Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
Authors Zhou P, Jiang Y, Hu X, Sun W, Liu Y, Pan Y, Luo R, Shao Z
Received 3 October 2015
Accepted for publication 8 March 2016
Published 18 April 2016 Volume 2016:9 Pages 2287—2295
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Chang Liu
Peer reviewer comments 3
Editor who approved publication: Professor Min Li
Ping Zhou,1–3 Yi-Zhou Jiang,4 Xin Hu,4 Wei Sun,4 Yi-Rong Liu,4 Fang Liu,5 Rong-Cheng Luo,1,* Zhi-Ming Shao4,*
1Department of Oncology, TCM-Integrated Cancer Center of Southern Medical University, Southern Medical University, Guangzhou, Guangdong, 2Department of Breast Surgery, The Third Hospital of Nanchang, 3Jiangxi Provincial Key Laboratory for Breast Diseases, Jiangxi, 4Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, 5Department of Pathophysiology, Foshan University, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Objective: The aim of this study was to describe the clinical features and outcomes of Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Method: The clinical data and survival statuses of 732 patients with operable HER2-positive breast cancer who were treated at the Department of Breast Surgery of the Shanghai Cancer Center from January 1, 2007, to December 31, 2011, were collected. The patients were divided into two groups according to treatment with and without trastuzumab. Disease-free survival (DFS) and overall survival were calculated using the Kaplan–Meier method and log-rank test. The associations of the patient characteristics with prognosis were analyzed via Cox regression.
Results: A total of 732 women with HER2-positive breast cancer were included in this study, among whom 258 (35.2%) received trastuzumab. The median follow-up duration was 41 months. By the end of the follow-up period, 86 (12%) women experienced local recurrence or metastasis. Patients who received both anti-HER2 therapy and chemotherapy exhibited a longer DFS than those who received chemotherapy alone (P=0.001). Tumor size, lymph node status, and family history of breast cancer were associated with median DFS, and tumor size, lymph node status, clinical stage, age, and body mass index were associated with median overall survival. Patients who received both neoadjuvant chemotherapy and trastuzumab exhibited a higher rate of pathological complete remission. In the neoadjuvant group, the patients who received both anti-HER2 therapy and chemotherapy exhibited a longer DFS than those who received chemotherapy alone (P=0.049).
Conclusion: Significant clinical features were observed in the Chinese patients with HER2-positive breast cancer. Furthermore, targeted anti-HER2 therapy may improve the prognosis of these patients.
Keywords: breast cancer, trastuzumab, HER2, disease-free survival, chemotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]